Research programme - targeted protein degrader therapeutics - Astellas Pharma/Cullgen
Latest Information Update: 07 Aug 2024
At a glance
- Originator Astellas Pharma; Cullgen
- Class Antineoplastics
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Breast cancer; Solid tumours
Most Recent Events
- 07 Aug 2024 Early research in Breast cancer in Japan, USA (unspecified route) prior to August 2024 (unspecified route) (Cullgen pipeline, August 2024)
- 07 Aug 2024 Early research in Solid tumours in Japan, USA (unspecified route) prior to August 2024 (unspecified route) (Cullgen pipeline, August 2024)
- 15 Jun 2023 Astellas Pharma and Cullgen agree to co-develop targeted protein degrader therapeutics for Breast cancer and Solid tumours